RSV MAT-004 - A Phase II observer-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women and infants born to vaccinated mothers
- Buttery, Jim (Primary Chief Investigator (PCI))
Project: Research